| KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ... Annals of Oncology 31 (12), 1746-1754, 2020 | 163 | 2020 |
| Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives E Krasniqi, G Barchiesi, L Pizzuti, M Mazzotta, A Venuti, M Maugeri-Saccà, ... Journal of hematology & oncology 12, 1-26, 2019 | 115 | 2019 |
| Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma F Goeman, F De Nicola, S Scalera, F Sperati, E Gallo, L Ciuffreda, ... Journal of Thoracic Oncology 14 (11), 1924-1934, 2019 | 71 | 2019 |
| CDK4/6 inhibitor treatments in patients with hormone receptor positive, Her2 negative advanced breast cancer: potential molecular mechanisms, clinical implications and future … M Roberto, A Astone, A Botticelli, L Carbognin, A Cassano, G D’Auria, ... Cancers 13 (2), 332, 2021 | 60 | 2021 |
| Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives G Barchiesi, M Mazzotta, E Krasniqi, L Pizzuti, D Marinelli, E Capomolla, ... International journal of molecular sciences 21 (10), 3528, 2020 | 57 | 2020 |
| Ketogenic diet and other dietary intervention strategies in the treatment of cancer M Vergati, E Krasniqi, G D Monte, S Riondino, D Vallone, F Guadagni, ... Current medicinal chemistry 24 (12), 1170-1185, 2017 | 57 | 2017 |
| Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study G Bon, L Pizzuti, V Laquintana, R Loria, M Porru, C Marchiò, E Krasniqi, ... Journal of Experimental & Clinical Cancer Research 39, 1-14, 2020 | 45 | 2020 |
| KEAP1 and TP53 frame genomic, evolutionary, and immunologic subtypes of lung adenocarcinoma with different sensitivity to immunotherapy S Scalera, M Mazzotta, G Corleone, F Sperati, I Terrenato, E Krasniqi, ... Journal of Thoracic Oncology 16 (12), 2065-2077, 2021 | 35 | 2021 |
| Long-term safety and real-world effectiveness of trastuzumab in breast cancer M Mazzotta, E Krasniqi, G Barchiesi, L Pizzuti, F Tomao, M Barba, P Vici Journal of clinical medicine 8 (2), 254, 2019 | 31 | 2019 |
| KEAP1-Mutant NSCLC: the catastrophic failure of a cell-protecting hub S Scalera, M Mazzotta, C Cortile, E Krasniqi, R De Maria, F Cappuzzo, ... Journal of Thoracic Oncology 17 (6), 751-757, 2022 | 30 | 2022 |
| Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence E Krasniqi, L Pizzuti, G Barchiesi, D Sergi, S Carpano, C Botti, R Kayal, ... Journal of Cellular Physiology 235 (11), 7900-7910, 2020 | 25 | 2020 |
| Prognostic relevance of neutrophil to lymphocyte ratio (NLR) in luminal breast cancer: a retrospective analysis in the neoadjuvant setting A Grassadonia, V Graziano, L Iezzi, P Vici, M Barba, L Pizzuti, G Cicero, ... Cells 10 (7), 1685, 2021 | 24 | 2021 |
| Circulating HPV DNA in the management of oropharyngeal and cervical cancers: current knowledge and future perspectives E Krasniqi, M Barba, A Venuti, L Pizzuti, F Cappuzzo, L Landi, S Carpano, ... Journal of Clinical Medicine 10 (7), 1525, 2021 | 23 | 2021 |
| Eribulin in triple negative metastatic breast cancer: critic interpretation of current evidence and projection for future scenarios L Pizzuti, E Krasniqi, G Barchiesi, M Mazzotta, M Barba, A Amodio, ... Journal of Cancer 10 (24), 5903, 2019 | 20 | 2019 |
| Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: Current evidence and literature-based meta-analysis of randomized trials D Marinelli, M Mazzotta, L Pizzuti, E Krasniqi, T Gamucci, C Natoli, ... Cancers 12 (9), 2497, 2020 | 16 | 2020 |
| Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes M Mazzotta, M Filetti, M Occhipinti, D Marinelli, S Scalera, I Terrenato, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 14 | 2020 |
| The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial L Pizzuti, M Barba, M Mazzotta, E Krasniqi, M Maugeri-Saccà, T Gamucci, ... Scientific Reports 11 (1), 13770, 2021 | 11 | 2021 |
| Palliative-and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives D Marinelli, R Giusti, M Mazzotta, M Filetti, E Krasniqi, L Pizzuti, L Landi, ... Critical reviews in oncology/hematology 157, 103176, 2021 | 11 | 2021 |
| Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma S Scalera, B Ricciuti, M Mazzotta, N Calonaci, JV Alessi, L Cipriani, G Bon, ... Annals of Oncology 34 (3), 275-288, 2023 | 10 | 2023 |
| MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study E Krasniqi, A Sacconi, D Marinelli, L Pizzuti, M Mazzotta, D Sergi, ... Biomarker research 9 (1), 57, 2021 | 10 | 2021 |
